Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03530163 · ClinicalTrials.gov registry record · NA
Breathing Training to Improve Human Performance at High Altitude
A NA study of Mountain Sickness Acute, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03530163: Completed NA study of Mountain Sickness Acute, sponsored by University of Colorado, Denver.
NCT03530163 is a NA study of Mountain Sickness Acute that has completed, run by University of Colorado, Denver. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03530163, a NA study of Mountain Sickness Acute, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals traveling to altitudes above 8,000 feet may suffer from impaired exercise and cognitive performance, and acute mountain sickness (AMS). Decreased barometric pressure, which leads to low blood oxygen levels, is the primary cause of these disorders. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue, and difficulty sleeping. The goal of this research is to identify whether Respiratory Muscle Training will improve physical and cognitive performance, and reduce the symptoms of AMS, at simulated high altitude.
Primary Outcome
Determine whether Respiratory Muscle Training performed 3x a week for 30 minutes per session is effective in improving exercise performance during acute simulated high-altitude exposure.
Conditions Studied
Interventions
- DEVICE Respiratory Muscle Training
- DEVICE Sham Breathing Training
Study Locations (1)
Colorado
- Altitude Research Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-08-09 |
| Est. Completion | 2020-01-15 |
| Phase | NA |
What the finished NCT03530163 record still lists
NCT03530163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Mountain Sickness Acute appearing as the primary indexed condition, and to 2 interventions - of which Respiratory Muscle Training is the first listed.
NCT03530163 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03530163 about?
NCT03530163 is a clinical study titled "Breathing Training to Improve Human Performance at High Altitude". Individuals traveling to altitudes above 8,000 feet may suffer from impaired exercise and cognitive performance, and acute mountain sickness (AMS). Decreased barometric pressure, which leads to low blood oxygen levels, is the primary cause of these disorders. Symptoms of AMS are characterized by hea...
What is the current status of trial NCT03530163?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2018-08-09. Estimated completion is 2020-01-15.
What conditions does trial NCT03530163 study?
This clinical trial studies the following conditions: Mountain Sickness Acute.
What interventions are being tested in trial NCT03530163?
The interventions under investigation include: Respiratory Muscle Training (DEVICE), Sham Breathing Training (DEVICE).
Who is sponsoring clinical trial NCT03530163?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03530163 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03530163's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI